Yvonne Gilliland, MD
Cardiovascular Disease · New Orleans, LANPI 1356309595
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Edwards Lifesciences at 29.7% of the total. 2025 is the largest year on record at $9,601, more than ten times the $254 reported in 2019.
Across 108 payments — averaging $117.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Abbott$4K
- E.r. Squibb & Sons, L.L.C.$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$463
- Medtronic$360
- Johnson & Johnson$348
- plus $1K from 12 others
What the payments were for
- Consulting fees$2,86523%
- Travel & lodging$4,56036%
- Food & beverage$5,25741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 21 | $3,764 |
| Abbott | 26 | $3,733 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,865 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $463 |
| Medtronic | 3 | $360 |
| Johnson & Johnson | 23 | $348 |
| Bard Peripheral Vascular, Inc. | 11 | $222 |
| Siemens Medical Solutions USA, Inc. | 2 | $220 |
| Inari Medical, Inc. | 1 | $161 |
| Atricure, Inc. | 2 | $161 |
| Abiomed | 1 | $149 |
| Livanova USA, Inc. | 2 | $72 |
| AstraZeneca | 3 | $49 |
| Pfizer | 3 | $48 |
| Novartis | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Amgen | 1 | $15 |
| GE HealthCare | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAVITOR$1,717
- PASCAL$1,535
- EVOQUE$1,306
- MitraClip$325
- COREVALVE EVOLUT R$212
- LifeVest$200
- FLOWTRIEVER CATHETER, S$161
- CT THROMBECTOMY SYSTEM KIT$161
- Mitra Clip system$149
- Impella$149
- RESOLUTE ONYX$148
- TRICLIP$122
- Artis icono$120
- GALLANT$118
- ACUSON Juniper Diagnostic Ultrasound System$101
How this compares
$12,683 in reported general payments places this provider in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $142,628 |
| EntrestoSacubitril/Valsartan | 98 | $96,543 |
| JardianceEmpagliflozin | 47 | $38,150 |
| Repatha SureclickEvolocumab | 36 | $28,226 |
| XareltoRivaroxaban | 29 | $23,698 |
| Praluent PenAlirocumab | 28 | $17,701 |
| Metoprolol Succinate | 170 | $1,824 |
| Atorvastatin Calcium | 205 | $1,662 |
| Rosuvastatin Calcium | 138 | $1,511 |
| Losartan Potassium | 139 | $816 |
| Ezetimibe | 70 | $717 |
| Amlodipine Besylate | 163 | $551 |
| Irbesartan | 19 | $412 |
| Spironolactone | 76 | $400 |
| Labetalol Hcl | 21 | $379 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $48 | $142,628140 claims |
| NovartisEntresto | $19 | $96,54398 claims |
| Johnson & JohnsonXarelto | $348 | $23,69829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Alexandra SanchezNew Orleans$69K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Frank WilklowNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.